Carag Receives U.S. FDA IDE Approval to Conduct Clinical Study of First Transcatheter Septal Occluder With Bioresorbable, Metal-free Framework
Baar, Switzerland (ots/PRNewswire) - The U.S. trial for CE-marked CBSO is designed to enroll up to 250 patients in a staged study approach CARAG AG, a privately-held Swiss medical device development company, today announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) ...
plus